A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment

Study Overview

The purpose of this study is to provide remdesivir (RDV) to participants with moderate COVID-19.

Study Description

Participants will be randomly assigned to receive either continued SOC therapy together with intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-5, or continued SOC therapy together with IV RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2-10.


  • IRB Number: 2003894138
  • Research Study Identifier: 2003894138
  • Principal Investigator: Samir Gupta, MD

Recruitment Status

Enrolling By Invitation

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.